Rosetta, Prometheus Settle Arbitration on MicroRNA Tests

Rosetta has regained US commercial rights from Prometheus for its miRview mets, miRview squamous, and miRview meso tests.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.